BIOMAT Database Logo BIOMAT Database Logo

Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma. 2017

Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV, 3, 16132 Genova, Italy.

In the last few years, several pyrrolo-pyrimidine derivatives have been either approved by the US FDA and in other countries for the treatment of different diseases or are currently in phase I/II clinical trials. Herein we present the synthesis and the characterization of a novel series of pyrrolo[2,3-d]pyrimidines, compounds 8a-j, and their activity against Glioblastoma multiforme (GBM). Docking studies and MM-GBSA analysis revealed the ability of such compounds to efficiently interact with the ATP binding site of Src. Enzymatic assays against a mini-panel of kinases (Src, Fyn, EGFR, Kit, Flt3, Abl, AblT315I) have been performed, showing an unexpected selectivity of our pyrrolo[2,3-d]pyrimidines for Src. Finally, the derivatives were tested for their antiproliferative potency on U87 GBM cell line. Compound 8h showed a considerable cytotoxicity effect against U87 cell line with an IC50 value of 7.1 μM.

UI MeSH Term Description Entries
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
December 2018, Bioorganic chemistry,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.
March 2001, Bioorganic & medicinal chemistry letters,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.
March 2001, Bioorganic & medicinal chemistry letters,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
October 2013, Journal of enzyme inhibition and medicinal chemistry,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src.
June 2002, Mini reviews in medicinal chemistry,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Pyrrolo [2,3-d] pyrimidines.
September 1968, Journal of pharmaceutical sciences,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
November 2017, Bioorganic & medicinal chemistry letters,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Identification and synthesis of substituted pyrrolo[2,3-d]pyrimidines as novel firefly luciferase inhibitors.
September 2012, Bioorganic & medicinal chemistry,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Pyrrolo[2,3-d]pyrimidines as EGFR and VEGFR kinase inhibitors: a comprehensive SAR review.
August 2023, Current medicinal chemistry,
Francesca Musumeci, and Anna Lucia Fallacara, and Chiara Brullo, and Giancarlo Grossi, and Lorenzo Botta, and Pierpaolo Calandro, and Mario Chiariello, and Miroslava Kissova, and Emmanuele Crespan, and Giovanni Maga, and Silvia Schenone
Discovery of new thieno[2,3-d]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment.
July 2023, Future medicinal chemistry,
Copied contents to your clipboard!